恒瑞医药：收到药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of multiple drug candidates, indicating progress in its research and development pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Heng Rui Medicine Co., Ltd., have received approval for clinical trials of SHR-9839 (sc) and HRS-4642 injection [1] - The subsidiary Shandong Shengdi Medicine Co., Ltd. has also received approval for clinical trials of HRS-2141 tablets (I) and (II) [1]